243 related articles for article (PubMed ID: 14761186)
1. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
3. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
Pisano C; Aulicino C; Vesci L; Casu B; Naggi A; Torri G; Ribatti D; Belleri M; Rusnati M; Presta M
Glycobiology; 2005 Feb; 15(2):1C-6C. PubMed ID: 15496501
[TBL] [Abstract][Full Text] [Related]
4. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
Casu B; Guerrini M; Naggi A; Perez M; Torri G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
Biochemistry; 2002 Aug; 41(33):10519-28. PubMed ID: 12173939
[TBL] [Abstract][Full Text] [Related]
5. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
6. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
Leali D; Belleri M; Urbinati C; Coltrini D; Oreste P; Zoppetti G; Ribatti D; Rusnati M; Presta M
J Biol Chem; 2001 Oct; 276(41):37900-8. PubMed ID: 11473122
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
9. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.
Lundin L; Larsson H; Kreuger J; Kanda S; Lindahl U; Salmivirta M; Claesson-Welsh L
J Biol Chem; 2000 Aug; 275(32):24653-60. PubMed ID: 10816596
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
11. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells.
Dell'Era P; Belleri M; Stabile H; Massardi ML; Ribatti D; Presta M
Oncogene; 2001 May; 20(21):2655-63. PubMed ID: 11420677
[TBL] [Abstract][Full Text] [Related]
12. Endothelial proteoglycans inhibit bFGF binding and mitogenesis.
Forsten KE; Courant NA; Nugent MA
J Cell Physiol; 1997 Aug; 172(2):209-20. PubMed ID: 9258342
[TBL] [Abstract][Full Text] [Related]
13. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation.
Foxall C; Wei Z; Schaefer ME; Casabonne M; Fugedi P; Peto C; Castellot JJ; Brandley BK
J Cell Physiol; 1996 Sep; 168(3):657-67. PubMed ID: 8816920
[TBL] [Abstract][Full Text] [Related]
14. Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2.
Ribatti D; Gualandris A; Belleri M; Massardi L; Nico B; Rusnati M; Dell'Era P; Vacca A; Roncali L; Presta M
J Pathol; 1999 Dec; 189(4):590-9. PubMed ID: 10629563
[TBL] [Abstract][Full Text] [Related]
15. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
16. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44.
Hibino S; Shibuya M; Hoffman MP; Engbring JA; Hossain R; Mochizuki M; Kudoh S; Nomizu M; Kleinman HK
Cancer Res; 2005 Nov; 65(22):10494-501. PubMed ID: 16288042
[TBL] [Abstract][Full Text] [Related]
17. Novel function of ascorbic acid as an angiostatic factor.
Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
[TBL] [Abstract][Full Text] [Related]
18. Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation.
Garmy-Susini B; Delmas E; Gourdy P; Zhou M; Bossard C; Bugler B; Bayard F; Krust A; Prats AC; Doetschman T; Prats H; Arnal JF
Circ Res; 2004 May; 94(10):1301-9. PubMed ID: 15073041
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of disaccharides derived from heparin and evaluation of effects on endothelial cell growth and on binding of heparin to FGF-2.
O'Brien A; Lynch C; O'Boyle KM; Murphy PV
Carbohydr Res; 2004 Oct; 339(14):2343-54. PubMed ID: 15388349
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic function of antithrombin is dependent on its conformational variation: implication for other serpins.
Azhar A; Singh P; Rashid Q; Naseem A; Khan MS; Jairajpuri MA
Protein Pept Lett; 2013 Apr; 20(4):403-11. PubMed ID: 23016581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
